r f
3.1.KÉT LUÂN
Tir câc két quâ nghiên cüu thu duoc chüng tôi rut ra mot so két luân sau: - Mire dô và toc dô hoà tan cüa PIRO trong HPTR vôi HP-|3-cyd, PVP tâng lên dang kë so vôi HHVL cô cùng thành phân và so vôi PIRO nguyên liêu.
- Tÿ lê duoc chât - chât mang cô ânh hucfng dén mire dô và tôc dô hoà tan cüa PIRO, trong pham vi khâo sât, dô hoà tan cüa PIRO tàng lên khi tÿ lê chât mang thân nuôc trong hê tàng.
- Mue dô và tôc dô hoà tan cüa PIRO trong HPTR ba thành phân tôt hon so vôi hê hai thành phân.
- Câc phuong phâp loai dung môi cô ânh huông dén müfc dô và tôc dô hoà tan cüa PIRO. Phuong phâp loai dung môi do bôc hoi trên câch thuÿ cho két quâ tôt hon câch loai dung môi bàng phuong phâp phun sây.
- Phân tich HPTR bàng phuong phâp quét pho nhiêu xa tia X, cho thây: Piroxicam trong HPTR ba thành phân PIRO/PVP/HP-(3-cyd tÿ lê 1:10:10 tôn tai hoàn toàn à trang thâi vô dinh hïnh. Két quâ này môt phân dâ giâi thich dô hoà tan cüa piroxicam tàng lên vôi su cô mât cüa PVP.
- Hê phân tân rân cüa PIRO vôi HP-(3-cyd tÿ lê 1:10 và HPTR ba thành phân PIRO/PVP/HP-(3-cyd tÿ lê 1:10:10 on dinh sau 1 thâng bâo quân à nhiêt dô phông thi nghiêm.
- Dâ lua chon duoc HPTR chüa PIRO dë dông vào nang và nhân thây: Dô hoà tan cüa PIRO tù viên nang ché bàng HPTR tôt hon so vôi viên nang chüa HHVL, nguyên liêu và viên nang dôi chiéu.
3.2. DÉ XUÂT
Tiép tue nghiên cüu theo dôi dô on dinh cûa viên nang PIRO ché tù HPTR dë cô thë huông tôi Crng dung vào thuc té sân xuât.
TÀI LIÊU THAM KHÂO
Tiëng Viêt
1. Bô mon bào ché (2002), Kÿ thuât bào ché và sinh duoc hoc câc dang thuôc, Nhà xuât ban Y hoc. I, II.
2. Bô mon Hoâ diroc, Truông Dai hoc Duoc Hà Nôi (2004), Hoà duoc tâp l,tr.l29.
3. Bô Y té (2003), Duoc diën Viêt Nam III, Tr. 227-228.
4. Bô Y té (2004), Duoc thu quoc gia Viêt Nam, Nhà xuât bân Y hoc.
5. Hoàng Minh Châu (2005), “Nghiên cüu dnh huông cüa mot so dung môi, tâ duoc và HP-fi-cyd tâi khâ nang giâi phông và hâ'p thu qua gia cüa piroxicam ” , Luân vàn thac sï duoc hoc.
6. Lê Thi Thu Trang (2005), “Nghiên cüu hê phân tân rân cüa Furosemid và ûng dung vào dang thuoc viên ” , Khoâ luân tôt nghiêp duoc si Dai hoc, Trucfng Dai Hoc Duoc Hà Nôi.
7. Nguyên Thi Hà (2002), “Nghiên cûu hê phân tân rân cüa Artemether, ûng dung vào dang thuoc dan ” , khoâ luân tôt nghiêp duoc sï Dai hoc, Trudng Dai Hoc Duoc Hà Nôi.
8. Nguyên Thi Thu Hà (2005), “Nghiên cüu hê phân tân rân cüa Indomethacin ” , Khoâ luân tôt nghiêp duoc si Dai hoc, Truôrng Dai Hoc Duoc Hà Nôi, Tr.4-11.
Tiëng Anh
9. A.Miro et al.(2004), “Improvement of gliquidone hypoglycacemic effect in rats by cyclodextrin formulation”, Eur. J. Pharm. Sci.,23, p.57-64.
10. Adriana Trapani et al.(2005), “A rapid screening tool for estimating the potential of 2-hydroxypropyl-(3-cyclodextrin complexation for solubilization purposes”, In. J. Pharm., 295, p. 163-175.
11. AHFS Drug Information (1998), p. 1660-1661.
12. Ashok C et al.(2005), “Isothermal titration calorimetry method for détermination of cyclodextrin complexation thermodynamics between artemisinin and naproxen under varying environmental conditios”, Eur. J. Pharm. Sci., 59, p.325-332.
13. Bounoure et al.(2006), “Solubility and dissolution rate of progesterone- cyclodextrin-polymer systems”, Drug Dev. Ind. Pharm., 32, p. 1043- 1058.
14. BP 2005.
15. Dan Wang et al.(2000), “Comparative population pharmacokinetic- pharmacodynamic analysis for piroxicam- (3-cyclodextrin and piroxicam”, J. Clin. Phdrm., 40, p .1257-1266.
16. Evangelos Karavas et al.(2005), “Miscibility behavior and felodipine- polyvinylpyrolidone amorphous solid dispersions”, Drug Dev. Ind. Pharm., 31, p. 473-489.
17. German L.Perlovich et al.(2003), “Driving forces and the influence of the buffer composition on the complexation reation between ibuprofen and HPCD”, Eur. J. Pharm. Sci., 20, p .197-200.
18. H.A. Salama et al.(2006), “Formulation and biological évaluation of glimepiride-cyclodextrin-polymer systems”, Int. J. Pharm., 309, p. 129- 138.
19. Hadi Valizadeh et al.(2007), “Préparation and characterization of solid dispersions of piroxicam with hydrophilic carriers”, Drug Dev. Ind. Pharm., 33, p.45-56. (adsbygoogle = window.adsbygoogle || []).push({});
20. Hasan Basan et al.(2001), “Quantitative détermination of piroxicam in a new formulation (piroxicam- (3-cyclodextrin) by derivative UV spectrophotometric method and HPLC”, J. Pharm. Bio. Anal., 26, p.171- 178.
21. Karl Kolter et al.(1991), “Interaction of NSAID with cyclodextrin and hydroxypropyl cyclodextrin derivatives”, Int. J. Pharm., 74, p.85-93. 22. Kim L.Larsen et al.(2005), “Phase solubility and structure of the
inclusion comples of prednisolon and 6a-methyl presnisolon with various cyclodextrins”, J. Pharm. Sci., 94, p.507-517.
23. M. Binhas et al.(2006), “Cyclodextrin inclusion complexes of the central analgésie drug nefopam”, Drug Dev. Ind. Pharm., 32, p. 1123- 1134.
24. Makiko Fujii et al.(2005), “Prepartion, characterization, and tableting of solid diepersion of indomethacin with crospovidone”, Int. J. Pharm., 293, p. 145-153.
25. Mamdouh M. Ghorab et al.(2004), “Tablet formulation containing meloxicam and (3- cyclodextrin: Mechanical characterization and bioavailability évaluation”, AAPS PharmSciTech, 5(4): article 59.
26. Mangal S. Nagarsenker et al.(2005), “Formulation studies and in vivo évaluation of a flurbiprofen-hydroxypropyl-(3-cyclodextrin system”,
Pharm. Dev. Tech., 1, p. 105-114.
27. Mara. B. L et al.(2004), “Influence of hydroxypropyl-(3-cyclodextrin complexation on piroxicam release from buccoadhesive tablets”, Eur. J. Pharm. Sci., 21, p.251-260.
28. Mario Jug et al.(2004), “Multicompoment complexes of piroxicam with cyclodextrin and hydroxypropyl methylcellulose”, Drug Dev. Ind. Pharm., 10, p .1051-1060.
29. MIMS Viêt Nam 2003.
30. N. Maleki et al.(2002), “Enhancement of dissolution rate and anti- inflammatory effects of piroxicam using solvent déposition technique”,
Drug Dev. Ind. Pharm., 28, p.681-686.
31. Nagesh Bandi et al.(2004), “Préparation of budesonide and indomethacin- hydroxypropyl-(3-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fruid process”, Eur. J. Pharm. Sci., 23, p .159-168.
32. Pablo Taboada et al.(2006), “Sertaconazole/hydroxypropyl-p- cyclodextrin complexation: isothermal titration calorimetry and solubility approaches”, J. Pharm. Sci., 95, p. 1751-1762.
33. Ryh-NanPan et al.(2000), “Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems”, Drug Dev. Ind. Pharm., 2, 9, p.984-994.
34. S. Basavaraj et al.(2006), “Bioavailability enhancemet of poorly water soluble and weakly acidic neu chemical entity with 2-hydroxy propyl-|3- cyclodextrin: selection of meglumine, a polyhydroxy base, as a novel temary component”, Pharm. Dev. Tech., 11, p. 443-451.
35. S. Srinivas et al.(2006), “Effect of polyvinylpyrrolidone on complexation and dissolution rate of [ beta ]-and hydroxypropyl-[beta]- cyclodextrin complexes of celecoxib”, Int. J. Pharm., 68, p.1-4.
36. Shan-Yang Lin et al.(1989), “Solid particulales of drug (3-cyclodextrin inclution complexes directly prepared by a spray-drying technique”, Int. J. Pharm., 56, p.249-259.
37. USP26.
38. V. Grangé et al.(2005), “Pharmacokinetic profiles of two tablet formulation of piroxicam”, Int. J. Pharm., 295, p.129-134.
39. V. Tantisihaiyakul et al.(1996), “Properties of solid dispersions of piroxicam in polyvinylpyrolidone K-30”, Int. J. Pharm., 143, p. 59-66. 40. Ya-Li-Zhao et al.(2004), “Cyclodextrin enhanced transdermal delivery
of piroxicam and carboxyfluorescein by electroporation”, J. Control. Rel., 99, p.393-402.
41. Yang Yu et al.(2003), “Study on inclusion interaction of piroxicam with P-cyclodextrin derivative”, Spec. Acta Part A., 59, p.3379-3386.
42. Yanhui Tang et al.(2006), “Characteristics of bicalutamide solid dispersions and improvement of the dissolution”, Drug Dev. Ind. Pharm., 32, p. 967-972.
43. Ying Zheng et al.(2005), “Physicochemical and structural characterization of quercetin- (3-cyclodextrin Complex”, J. Pharm. Sci., 94, 5, p .1079-1089.
44. Yukio Aso et al.(2006), “Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid dispersions as measured by C-NMR spin-lattice relaxation time”, J. Pharm. Sci.,95, p. 318-325.